Name that Hu­mi­ra biosim­i­lar: In­side the com­pli­cat­ed process to brand the newest ver­sions of Ab­b­Vie's drug

Sev­en new drugs launched last week, all with re­sound­ing sim­i­lar­i­ty — and all try­ing to cap­ture a piece of the lu­cra­tive mar­ket for Ab­b­Vie’s Hu­mi­ra.

The drugs are all FDA-ap­proved biosim­i­lars for Hu­mi­ra, or adal­i­mum­ab, still one of the world’s top-sell­ing drugs and a com­mon treat­ment for pso­ri­a­sis and arthri­tis. The group joins Am­gen’s Am­je­vi­ta, which hit the mar­ket in Jan­u­ary, and Pfiz­er’s Abri­la­da, set to launch this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER